MR Spectroscopy in Diagnosis and Neurological Decision-Making

Victor Xu; Henry Chan; Alexander P. Lin; Napapon Sailasuta; Samuel Valencerina; Thao Tran; Jan Hovener; Brian D. Ross

doi:10.1055/s-0028-1083685

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2008; 28(4): 407-422
DOI: 10.1055/s-0028-1083685

MR Spectroscopy in Diagnosis and Neurological Decision-Making

Victor Xu¹ ^, ² , Henry Chan¹ , Alexander P. Lin¹ ^, ² , Napapon Sailasuta¹ ^, ² , Samuel Valencerina³ , Thao Tran¹ ^, ² , Jan Hovener¹ , Brian D. Ross¹ ^, ²

¹Clinical Magnetic Resonance Unit, Huntington Medical Research Institutes, Pasadena, California
²Rudi Schulte Research Institute, Santa Barbara, California
³University Hospital Imaging Center, University of Southern California, Los Angeles, California

Abstract

ABSTRACT

One of the most prolific chemical and anatomical imaging techniques of recent decades, magnetic resonance imaging (MRI), includes the ability to noninvasively assess neurochemical changes with magnetic resonance spectroscopy (MRS). Practical concerns are paramount in applying MRS, such as what the manufacturer provides with a routine MRI scanner, what methods are well tolerated by patients, and what has proved most diagnostically productive over a 25 year span of preliminary exploration of the technology. In this review, the authors explain the technical and neurochemical aspects of MRS and critically discuss its clinical neuroimaging applications.

KEYWORDS

MRI - spectroscopy - metabolite - N-acetylaspartate - choline - creatine

Volltext

Referenzen

REFERENCES

1 Danielsen E R, Ross B D. Magnetic Resonance Spectroscopy in Diagnosis of Neurological Diseases. New York; Marcel Dekker 2000
2 Gillard J, Waldman A, Barker P Clinical MR Neuroimaging. Cambridge, UK; Cambridge University Press 2005
3 Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec. 2001; 265 54-84
4 Lin A, Nguy C-H, Shic F et al.. Accumulation of methylsulfonylmethane (MSM) in the human brain: identification by magnetic resonance spectroscopy. Toxicol Lett. 2001; 123 169-177
5 Hoevener J, Lin A, Tran T et al.. Neurospectroscopy will miss the boat—AGAIN: the need for universal standards and database. Proceedings of International Society for Magnetic Resonance in Medicine Germany; May 2007
6 Harris K, Lin A, Bhattacharya P et al.. Regulation of NAA-synthesis in the human brain in vivo: Canavan's disease, Alzheimer's disease and schizophrenia. Adv Exp Med Biol. 2006; 576 263-273
7 Haseler L J, Arcinue E, Danielsen E R et al.. Evidence from proton magnetic resonance spectroscopy for a metabolic cascade of neuronal damage in shaken baby syndrome. Pediatrics. 1997; 99 4-14
8 Govindaraju V, Young K, Maudsley A A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13 129-153
9 Burtscher I M, Skagerberg G, Geijer B et al.. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol. 2000; 21 84-93
10 Hollingworth W, Medina L S, Lenkinski R E et al.. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol. 2006; 27 1404-1411
11 Chernov M F, Hayashi M, Izawa M et al.. Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases. Brain Tumor Pathol. 2006; 23 19-27
12 Schlemmer H P, Bachert P, Henze M et al.. Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. Neuroradiology. 2002; 44 216-222
13 Hinchey J, Chaves C, Appignani B et al.. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334 494-500
14 Wang H C, Cheng S J. The syndrome of acute bilateral basal ganglia lesions in diabetic uremic patients. J Neurol. 2003; 250 948-955
15 Lin A P, Tran T T, Ross B D. Impact of evidence-based medicine on magnetic resonance spectroscopy: clinical practice, reimbursement, and solutions. NMR Biomed. 2006; 19 476-483
16 Clinical Policy Bulletin: Magnetic Resonance Spectroscopy (MRS). April 13, 2007. Available at: http://www.aetna.com/cpb/medical/data/200_299/0202.html Accessed January 2, 2008
17 De Stefano N, Filippi M, Miller D et al.. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology. 2007; 69 1942-1952
18 Lin A, Shic F, Zapata M et al.. Magnetic resonance spectroscopy diagnosis of Alzheimer Disease: verification at autopsy. Neurobiol Aging. 2002; 23 S465
19 Lin A, Enriquez C, Ross B D. 1H magnetic resonance spectroscopy detection of chromosomal defects in Alzheimer's disease and Down syndrome. Proceedings from 11th International Society for Magnetic Resonance in Medicine 2003
20 Godbolt A K, Waldman A D, MacManus D G et al.. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology. 2006; 66 718-722
21 Adalsteinsson E, Sullivan E V, Kleinhans N, Spielman D M, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000; 355 1696-1697
22 Sailasuta N, Shriner K, Ross B. Evidence of decreased glutamate in the frontal lobe of HIV patients. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections Boston; 2008 Poster E-168
23 Patil S T, Zhang L, Martenyi F et al.. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007; 13 1102-1107
24 Weinberger D R. Schizophrenia drug says goodbye to dopamine. Nat Med. 2007; 13 1018-1019
25 Blüml S, Moreno-Torres A, Shic F et al.. Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed. 2002; 15 1-5
26 Harris K C, Bhattacharya P, Lin A P et al.. Apparent glutamate neurotransmitter rate is reduced in schizophrenic humans: a 1-13C glucose MRS study. Proceedings of the 21st Annual Scientific Meeting, ESMRMB 2004, Denmark Abstract 62:S31
27 Siddall P J, Stanwell P, Woodhouse A et al.. Magnetic resonance spectroscopy detects biochemical changes in the brain associated with chronic low back pain: a preliminary report. Anesth Analg. 2006; 102 1164-1168
28 Somorjai R L, Dolenko B, Nikulin A K et al.. Classification of 1H MR spectra of human brain neoplasms: the influence of preprocessing and computerized consensus diagnosis on classification accuracy. J Magn Reson Imaging. 1996; 6 437-444
29 Bluml S, Kopyov O, Jacques S, Ross B D. Activation of neurotransplants in humans. Exp Neurol. 1999; 158 121-125
30 Hoang T Q, Bluml S, Dubowitz D J et al.. Quantitative proton-decoupled ³¹P MRS and ¹H MRS in the evaluation of Huntington's and Parkinson's Diseases. Neurology. 1998; 50 1033-1040
31 Ross B D. Long-term fetal cell transplant in Huntington disease: stayin' alive. Neurology. 2008; 70 815-816
32 Manganas L N, Zhang X, Li Y et al.. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science. 2007; 318 980-985
33 Stoica P, Sandgren N, Selen Y et al.. Frequency-domain method based on the singular value decomposition for frequency-selective NMR spectroscopy. J Magn Reson. 2003; 165 80-88
34 Mekle1 R, Gruetter R. Comparison of a TEM head coil with an 8 channel head array coil at 3 Tesla. Proceedings from 14th International Society for Magnetic Resonance in Medicine 2006
35 Golman K, Ardenkjaer-Larsen J H, Petersson J S et al.. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A. 2003; 100 10435-10439
36 Bhattacharya P, Harris K, Lin A et al.. Ultrafast three dimensional free precession imaging. MAGMA. 2005; 18 245-256
37 Shic F, Lin A, Shelden C H et al.. Definition of the neurochemical patterns of human head injury in 1H MRS using wavelet analysis. Proceedings from 9th International Society for Magnetic Resonance in Medicine 2001
38 Provencher S W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993; 30 672-679

Brian D RossM.D.

10 Pico Street, Pasadena

CA 91105

eMail: mrs@hmri.org